ANAB news today — last 24 hours, 7 days, 30 days

ANAPTYSBIO INC (ANAB) — News & AI sentiment

ANAPTYSBIO INC (ANAB) news roundup. 6 stories aggregated over the last 30 days. Average 30-day sentiment is 61.3/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 1 sales totalling $249K — net selling of $249K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

7d stories

30d stories

avg sentiment 61.3/100

Insider net (90d)

$249K

0 buys · 1 sells

Congress (90d)

0 buys · 0 sells

ANAB news in the last 24 hours, 7 days, 30 days and 90 days

How much ANAB coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	ANAB stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	0	—	no coverage
Last 30 days	6	61.3/100	ANAB headlines →
Last 90 days	22	55/100	ANAB headlines →

Latest stories on ANAB

AnaptysBio quickly drops amid hearing on GSK/Tesaro contract breach

Seeking Alpha34 · bearishgeneral

Oct 20

AnaptysBio Shares Gain on FDA Approval for Rectal Cancer Drug

Morningstar74 · bullishproduct/pr

Oct 19

AnaptysBio notes Jemperli approved in U.S. for locally advanced rectal cancer

The Fly74 · bullishproduct/pr

Oct 19

AnaptysBio gains as GSK granted FDA label expansion for Jemperli

Seeking Alpha74 · bullishproduct/pr

Oct 19

AnaptysBio: Fully Valued -- With Major Litigation Uncertainty

Seeking Alpha38 · neutralgeneral

Oct 13

Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed More Than 25%

Investors.com74 · bullishproduct/pr

Oct 12

AnaptysBio price target lowered to $60 from $70 at JPMorgan

The Fly34 · bearishanalyst

Sep 30

AnaptysBio price target lowered to $81 from $90 at Leerink

The Fly38 · neutralanalyst

Sep 23

AnaptysBio earnings analysis: questions answered and next catalysts

Investing.com Markets56 · neutralearnings

Sep 22

Why is AnaptysBio stock rising afterhours today?

Investing.com Markets55 · neutralgeneral

Sep 22

AnaptysBio reports Q2 diluted EPS $5.11 vs. ($1.30) last year

The Fly63 · neutralearnings

Sep 21

AnaptysBio GAAP EPS of $5.11 beats by $5.02, revenue of $27.5M beats by $7.38M

Seeking Alpha68 · bullishearnings

Sep 21

ANAPTYSBIO, INC (ANAB) files 8-K

SEC 8-K50 · neutralgeneral

Sep 21

Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)

Yahoo Finance57 · neutralgeneral

Sep 9

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

Business Insider56 · neutralgeneral

Sep 1

AnaptysBio stock rating maintained at Outperform by Wolfe Research

Investing.com Analyst Ratings61 · neutralanalyst

Aug 31

TD Cowen lowers Anaptysbio stock price target to $70 on FDA review

Investing.com Analyst Ratings38 · neutralanalyst

Aug 25

AnaptysBio price target lowered to $70 from $75 at TD Cowen

The Fly42 · neutralanalyst

Aug 25

AnaptysBio options imply 5.0% move in share price post-earnings

The Fly56 · neutralearnings

Aug 17

GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control

Yahoo Top63 · neutralm&a

Aug 17

AnaptysBio options imply 7.0% move in share price post-earnings

The Fly56 · neutralearnings

Aug 16

ANAPTYSBIO, INC (ANAB) files 8-K

SEC 8-K50 · neutralgeneral

Aug 11

AnaptysBio Enters Key Post-Trial Phase in Tesaro Dispute

TipRanks50 · neutralgeneral

Jul 30

ANAPTYSBIO, INC (ANAB) files 8-K

SEC 8-K50 · neutralgeneral

Jul 30

AnaptysBio: The Royalty Waterfall Is About To Reverse

Seeking Alpha63 · neutralproduct/pr

Jul 29